Compare BDC & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BDC | APGE |
|---|---|---|
| Founded | 1902 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.7B |
| IPO Year | 1994 | 2023 |
| Metric | BDC | APGE |
|---|---|---|
| Price | $137.59 | $134.59 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 13 |
| Target Price | ★ $162.50 | $109.67 |
| AVG Volume (30 Days) | 484.9K | ★ 1.1M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | ★ 0.16% | N/A |
| EPS Growth | ★ 23.13 | N/A |
| EPS | ★ 3.04 | N/A |
| Revenue | ★ $2,715,194,000.00 | N/A |
| Revenue This Year | $8.91 | N/A |
| Revenue Next Year | $4.70 | N/A |
| P/E Ratio | $44.70 | ★ N/A |
| Revenue Growth | ★ 10.33 | N/A |
| 52 Week Low | $98.00 | $35.39 |
| 52 Week High | $159.99 | $134.88 |
| Indicator | BDC | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 73.08 | 76.53 |
| Support Level | $102.61 | $134.03 |
| Resistance Level | $149.84 | $134.88 |
| Average True Range (ATR) | 4.87 | 0.23 |
| MACD | 1.83 | -0.92 |
| Stochastic Oscillator | 95.03 | 60.59 |
Belden Inc is a supplier of complete connection solutions. It has two segments, Smart Infrastructure Solutions and Automation Solutions. Smart Infrastructure Solutions provides network infrastructure and broadband solutions, serving markets such as data centers, government, healthcare, and broadband and wireless service providers, with products including copper and fiber cable and connectivity solutions. Automation Solutions provides digitization and automation solutions that enable IT OT convergence and support acquisition, transmission, orchestration, and management, serving markets including Warehousing and Logistics, Energy, Transportation, and Discrete Manufacturing. The company operates in the Americas, EMEA, and APAC, with maximum revenue coming from the Americas.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.